MRI biomarkers in osseous tumors.
Although radiography continues to play a critical role in osseous tumor assessment, there have been remarkable advances in cross-sectional imaging. MRI has taken a lead in this assessment due to high tissue contrast and spatial resolution, which are well suited for bone lesion assessment. More recently, although somewhat lagging other organ systems, quantitative parameters have shown promising potential as biomarkers for osseous tumors. Among these sequences are chemical shift imaging (CSI), apparent diffusion coefficient (ADC), and intravoxel incoherent motion (IVIM) from diffusion-weighted imaging (DWI), quantitative dynamic contrast enhanced (DCE)-MRI, and magnetic resonance spectroscopy (MRS). In this article, we review the background and recent roles of these quantitative MRI biomarkers for osseous tumors. Level of Evidence: 3 Technical Efficacy Stage: 3 J. MAGN. RESON. IMAGING 2019. J. Magn. Reson. Imaging 2019;50:702-718.
['Fukuda|Takeshi|T|', 'Wengler|Kenneth|K|0000-0002-8153-5183', 'de Carvalho|Ruben|R|', 'Boonsri|Pattira|P|', 'Schweitzer|Mark E|ME|']
D014408:Biomarkers, Tumor D001859:Bone Neoplasms D001842:Bone and Bones D006801:Humans D007090:Image Interpretation, Computer-Assisted D008279:Magnetic Resonance Imaging
biomarker osseous tumor bone tumor magnetic resonance imaging quantification sarcoma